AARP Features Maureen Maguire Vision Loss Study

AARP Features Maureen Maguire Vision Loss Study

LDI Senior Fellow Maureen Maguire's study of drugs for treating age-related macular degeneration (AMD) is featured in the AARP Bulletin. The research project essentially showed that $50-per-dose Avastin is as effective a treatment as the $2,000-per-dose Lucentis. "The impact on vision is virtually the same, no matter which drug is used," said Maguire, PhD, corresponding author on the study and director of Penn's Center for Preventive Ophthalmology and Biostatistics.